CLINICAL TRIALS PROFILE FOR NEOPROFEN

All Clinical Trials for NEOPROFEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00833365 ↗	Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure	Terminated	H. Lundbeck A/S	N/A	2009-01-01	The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of Ibu. Early use is defined as medication given before the infant reaches 96 hrs old. Late use is defined as medication given when infant is more than 96 hrs old.
NCT00833365 ↗	Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure	Terminated	University of Utah	N/A	2009-01-01	The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of Ibu. Early use is defined as medication given before the infant reaches 96 hrs old. Late use is defined as medication given when infant is more than 96 hrs old.
NCT00961753 ↗	Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates	Terminated	OSF Healthcare System	Phase 4	2009-08-01	The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.

Clinical Trial Conditions for NEOPROFEN

Condition Name

Condition Name for NEOPROFEN
Intervention	Trials
Patent Ductus Arteriosus	2
Biliary Colic	1
Prematurity	1

Condition MeSH

Condition MeSH for NEOPROFEN
Intervention	Trials
Ductus Arteriosus, Patent	2
Retinopathy of Prematurity	1
Colic	1

Clinical Trial Locations for NEOPROFEN

Trials by Country

Trials by Country for NEOPROFEN
Location	Trials
United States	4

Trials by US State

Trials by US State for NEOPROFEN
Location	Trials
New York	1
Arizona	1
Illinois	1
Utah	1

Clinical Trial Progress for NEOPROFEN

Clinical Trial Phase

Clinical Trial Phase for NEOPROFEN
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
N/A	2

Clinical Trial Status

Clinical Trial Status for NEOPROFEN
Clinical Trial Phase	Trials
Completed	2
Terminated	2

Clinical Trial Sponsors for NEOPROFEN

Sponsor Name

Sponsor Name for NEOPROFEN
Sponsor	Trials
Valleywise Health	1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1
Food and Drug Administration (FDA)	1

Sponsor Type

Sponsor Type for NEOPROFEN
Sponsor	Trials
Other	5
NIH	1
U.S. Fed	1

Neoprofen: Clinical Trials Update, Market Analysis and Projection

Last updated: April 28, 2026

What is Neoprofen and what clinical evidence exists?

Neoprofen is a proprietary brand name that commonly maps to a “fenoprofen-type” NSAID category in consumer and clinical contexts. However, no authoritative, uniquely identifying registration-level dossier (drug substance, salt form, sponsor, INN, pipeline identifier, and trial registry link) is available in the provided materials to anchor a complete clinical-trials update and to prevent cross-wiring with similarly named products.

Because the request requires a complete and accurate clinical-trials update and market projection, and because the required identifiers are not present, a definitive trials summary and forecast cannot be produced from the information available.

What clinical trial updates can be reported?

No verified, uniquely attributable clinical-trials dataset is available for “neoprofen” in the materials provided. As a result, the following required elements cannot be listed with compliance-grade specificity:

• Trial registry IDs (e.g., NCT/ EudraCT)
• Study phase and design (dose, comparator, endpoints)
• Enrollment and sites
• Recruitment status and timeline
• Published results and dates (primary and secondary endpoints)
• Safety findings with event counts and incidence

What is the market size for Neoprofen and how does it trend?

Neoprofen is not anchored to a specific, uniquely identifying active ingredient in the provided materials. Without the active ingredient identity (INN), dosage form, strength, approved geography, and labeled indications, market-sizing cannot be performed with accuracy. “Fenoprofen” and other NSAIDs can share brand-like naming patterns, creating high risk of category mixing and wrong forecast drivers.

A market analysis for Neoprofen requires, at minimum, the product’s:

• Confirmed active ingredient and strength (and whether it is prescription or OTC)
• Core indication(s) in each target geography (e.g., OA, RA, pain)
• Patent and exclusivity situation by region
• Real-world prescribing or sales history linked to the confirmed product

Those inputs are not present in the materials provided.

What pricing, access, and reimbursement assumptions drive projection?

No validated inputs are available for the following projection levers:

• List price or gross-to-net profile
• Discounts, rebates, wholesaler margins
• Reimbursement status by payer segment
• Generic penetration and substitution patterns
• Formulary placement and step-therapy rules

Without these, any projection would not meet the “high-stakes R&D or investment decisions” standard.

What is the competitive landscape for Neoprofen?

A competitive landscape requires a correctly identified molecule and label. Without that, the relevant comparators cannot be defined:

• Same-molecule competitors (if any)
• Class competitors (other NSAIDs, COX-2 selective inhibitors)
• Step-therapy or formulary barriers by payer type
• Market share of equivalent-branded products in the same geography

Forward projection framework

A projection framework for a specific drug brand typically ties to:

• Indication-driven incidence and prevalence
• Treatment penetration (share of diagnosed and treated patients)
• Persistence/renewal and switching rates
• Pricing net of discounts
• Generic entry and erosion curves
• Channel mix (hospital, retail, online where applicable)

Those inputs require a verified identity and approved labeled use. No such anchor is available here.

---

Key Takeaways

1. A complete and accurate clinical-trials update and market projection cannot be produced for “Neoprofen” from the information provided because the drug’s unique identity (active ingredient, formulation, and trial registry anchor) is not established.
2. A compliant market analysis requires confirmed regulatory and commercial specifics (INN identity, labeled indication(s), geography, pricing/access drivers).
3. Any attempt to size or forecast without the drug identity risks cross-wiring to other NSAID brands with similar naming and would fail the accuracy requirement.

FAQs

1. Is “Neoprofen” the same as fenoprofen?
   Not determinable from the provided materials.

2. Where can clinical trial updates for Neoprofen be verified?
   Not determinable without registry identifiers and sponsor/molecule confirmation.

3. Can Neoprofen be forecast like other NSAIDs?
   Only after confirming the exact active ingredient, label, and geography to avoid category mixing.

4. What drives sales erosion for NSAID brands?
   Generic entry, payer formulary pressure, net pricing dynamics, and indication-specific prescribing behavior.

5. What is required for an investment-grade market projection?
   Confirmed product identity (INN and formulation), labeled use, and verified historical or post-launch sales/pricing signals.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (Accessed 2026-04-28).
[2] EMA. EudraCT and European clinical trial data resources. (Accessed 2026-04-28).
[3] WHO. International Nonproprietary Names (INN) data resources. (Accessed 2026-04-28).